Acetaminophen Hepatotoxicity: Strong Offense and Weakened Defense
Neil Kaplowitz, Tin Aung Than, Sanda Win – 17 February 2020
Living Donor Liver Transplantation From Hepatitis C–Infected Donor to Hepatitis C–Infected Recipient
Henrik Junger, Birgit Knoppke, Kilian Weigand, Katja Evert, Frank W. Brennfleck, Michael Melter, Hans J. Schlitt, Stefan M. Brunner – 17 February 2020
Treatment of Hepatocellular Carcinoma in the Precision Medicine Era: From Treatment Stage Migration to Therapeutic Hierarchy
Alessandro Vitale, Franco Trevisani, Fabio Farinati, Umberto Cillo – 16 February 2020 – Treatment allocation is extremely complex in patients with hepatocellular carcinoma (HCC) because this neoplasm arises, in most cases, in patients with cirrhosis and additional comorbidities. The “stage hierarchy” approach, which involves linking each stage (or substage) of the disease to a specific treatment, has become the main proposed treatment strategy for the clinical management of HCC, particularly in the West.
Lipopolysaccharide Reverses Hepatic Stellate Cell Activation Through Modulation of cMyb, Small Mothers Against Decapentaplegic, and CCAAT/Enhancer‐Binding Protein C/EBP Transcription Factors
Akanksha Sharma, Alok K. Verma, Matthew Kofron, Ramesh Kudira, Alexander Miethke, Tong Wu, Jiang Wang, Chandrashekhar R. Gandhi – 16 February 2020
Reply
Nikhil Kapila, Asad Ur Rahman, Xaralambos B. Zervos – 16 February 2020
Treatment of Hepatocellular Carcinoma in the Precision Medicine Era: From Treatment Stage Migration to Therapeutic Hierarchy
Alessandro Vitale, Franco Trevisani, Fabio Farinati, Umberto Cillo – 16 February 2020 – Treatment allocation is extremely complex in patients with hepatocellular carcinoma (HCC) because this neoplasm arises, in most cases, in patients with cirrhosis and additional comorbidities. The “stage hierarchy” approach, which involves linking each stage (or substage) of the disease to a specific treatment, has become the main proposed treatment strategy for the clinical management of HCC, particularly in the West.
Hepatitis C Vaccine: 10 Good Reasons for Continuing
Philippe Roingeard, Elodie Beaumont – 15 February 2020
Endothelial Leukocyte Cell–Derived Chemotaxin 2/Tyrosine Kinase With Immunoglobulin‐Like and Epidermal Growth Factor–Like Domains 1 Signaling in Liver Fibrosis
Tingting Su, Yasuko Iwakiri – 15 February 2020
Fecal Microbiome Distinguishes Alcohol Consumption From Alcoholic Hepatitis But Does Not Discriminate Disease Severity
Ekaterina Smirnova, Puneet Puri, Mark D. Muthiah, Kalyani Daitya, Robert Brown, Naga Chalasani, Suthat Liangpunsakul, Vijay H. Shah, Kayla Gelow, Mohammed S. Siddiqui, Sherry Boyett, Faridoddin Mirshahi, Masoumeh Sikaroodi, Patrick Gillevet, Arun J. Sanyal – 14 February 2020
Role of Molecular Biomarkers in Liver Transplantation for Hepatocellular Carcinoma
Johann Felden, Augusto Villanueva – 14 February 2020 – Patient selection and organ allocation for liver transplantation (LT) in patients with hepatocellular carcinoma (HCC) relies predominantly on clinical parameters, such as tumor burden (ie, radiological imaging). Patients transplanted within Milan criteria have outstanding outcomes with a 5‐ and 10‐year survival of 70% and 55%, respectively. Tumor recurrence after transplantion is rare in these patients (10%); however, treatment options upon recurrence are generally limited, and outcomes are poor.